Top Story

pSivida completes enrollment for phase 3 trial of Medidur for posterior uveitis

March 27, 2015

pSivida completed the target enrollment of 120 patients in a phase 3 clinical trial of Medidur to treat posterior uveitis, according to a press release.

The double-masked study will compare Medidur vs. sham injections on a two-to-one basis to determine recurrence of posterior uveitis within 1 year. Patients are enrolled at centers in the United States, the European Union and India.

Business News

Enhanced BLIS injector system available from Bausch + Lomb

March 27, 2015
An enhanced BLIS injector system is now available, Bausch + Lomb announced in a press release.BLIS was designed exclusively for use with the enVista hydrophobic acrylic…
Meeting News Coverage

Telescope implant receives expanded indication, reimbursement

March 27, 2015
NEW YORK – VisionCare announced here at Vision Expo East that the FDA expanded the indication for its telescope implant to include patients as young as 65 years…
Meeting News Coverage

CooperVision announces new silicone hydrogel daily disposable

March 27, 2015
NEW YORK – Following the successful launch of the Clariti 1 day family of lenses, CooperVision prepares to introduce another lens in this category to practitioners…
CME
Postoperative Inflammation and Pain

Postoperative Inflammation and Pain: Elimination of the Dynamic Duo to Improve Patient Outcomes

This activity is supported by an educational grant from Bausch + Lomb.

Cataract surgery has improved in both safety and outcomes in recent years. With advances in surgical techniques…
More »
Meeting News Coverage Video
thumbnail for video 4012733766001

VIDEO: SightLife CEO updates global cornea transplantation achievements, goals

February 4, 2015
WAILEA, Hawaii – At Hawaiian Eye 2015, Monty Montoya, president and CEO of SightLife, discusses the…
More »
Business News

pSivida completes enrollment for phase 3 trial of Medidur for posterior uveitis

March 27, 2015
pSivida completed the target enrollment of 120 patients in a phase 3 clinical trial of Medidur to treat posterior uveitis, according to a press…
Business News

Enhanced BLIS injector system available from Bausch + Lomb

March 27, 2015
An enhanced BLIS injector system is now available, Bausch + Lomb announced in a press release.BLIS was designed exclusively for use with the enVista…
Meeting News Coverage

Telescope implant receives expanded indication, reimbursement

March 27, 2015
NEW YORK – VisionCare announced here at Vision Expo East that the FDA expanded the indication for its telescope implant to include patients as…
Meeting News Coverage

CooperVision announces new silicone hydrogel daily disposable

March 27, 2015
NEW YORK – Following the successful launch of the Clariti 1 day family of lenses, CooperVision prepares to introduce another lens in this…
Meeting News Coverage

QSpex to introduce same-day eye wear in New York

March 26, 2015
NEW YORK – QSpex announced it plans to launch a QSpex Optical Service Center in New York City this summer. QSpex President and Chief Executive…
Meeting News Coverage

Essilor focuses on patient safety, uncorrected refractive error

March 25, 2015
NEW YORK – Executives from Essilor and its Vision Impact Institute shared a number of the company’s initiatives here at a press…
Business News

ThromboGenics reports net loss in 2014

March 24, 2015
ThromboGenics reported a net loss of €51.1 million in 2014, compared with a net profit of €26.4 million in 2013, according to a press release.In…
Meeting News Coverage

Adlens plans June launch for variable focusing spectacles

March 24, 2015
NEW YORK – Adlens announced it will launch AdlensFocuss, its adjustable focus lens for presbyopes, in June.Adlens senior vice president David…
Breaking News

Akorn launches phenylephrine HCl ophthalmic solution

March 23, 2015
Akorn has launched a phenylephrine HCl ophthalmic solution, USP, 2.5% and 10% for pupil dilation, according to a press release.In January, the FDA…
Business News

Omeros reports net loss of $73.7 million in 2014

March 23, 2015
Omeros reported a net loss of $73.7 million, or $2.22 per share, in 2014 compared with $39.8 million, or $1.39 per share, in 2013, according to a…
More Headlines »
morganatic-roan
morganatic-roan